One advantage of this method is that the additional test used in the diagnostic workup for myeloma, serum protein electrophoresis, immunofixation, and serum-free light chain assays are sensitive and specific initial tests for the majority of patients and relatively inexpensive compared to other diagnostic methods. The gene discussed is TNFSF14; the disease is plasma cell myeloma.